These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 37267517)

  • 41. PRMT5 is required for cell-cycle progression and p53 tumor suppressor function.
    Scoumanne A; Zhang J; Chen X
    Nucleic Acids Res; 2009 Aug; 37(15):4965-76. PubMed ID: 19528079
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Combined inhibition of Chk1 and Wee1 as a new therapeutic strategy for mantle cell lymphoma.
    Chilà R; Basana A; Lupi M; Guffanti F; Gaudio E; Rinaldi A; Cascione L; Restelli V; Tarantelli C; Bertoni F; Damia G; Carrassa L
    Oncotarget; 2015 Feb; 6(5):3394-408. PubMed ID: 25428911
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Constitutive activation of Akt contributes to the pathogenesis and survival of mantle cell lymphoma.
    Rudelius M; Pittaluga S; Nishizuka S; Pham TH; Fend F; Jaffe ES; Quintanilla-Martinez L; Raffeld M
    Blood; 2006 Sep; 108(5):1668-76. PubMed ID: 16645163
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Disordered methionine metabolism in MTAP/CDKN2A-deleted cancers leads to dependence on PRMT5.
    Mavrakis KJ; McDonald ER; Schlabach MR; Billy E; Hoffman GR; deWeck A; Ruddy DA; Venkatesan K; Yu J; McAllister G; Stump M; deBeaumont R; Ho S; Yue Y; Liu Y; Yan-Neale Y; Yang G; Lin F; Yin H; Gao H; Kipp DR; Zhao S; McNamara JT; Sprague ER; Zheng B; Lin Y; Cho YS; Gu J; Crawford K; Ciccone D; Vitari AC; Lai A; Capka V; Hurov K; Porter JA; Tallarico J; Mickanin C; Lees E; Pagliarini R; Keen N; Schmelzle T; Hofmann F; Stegmeier F; Sellers WR
    Science; 2016 Mar; 351(6278):1208-13. PubMed ID: 26912361
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Combined inhibition of MTAP and MAT2a mimics synthetic lethality in tumor models via PRMT5 inhibition.
    Bedard GT; Gilaj N; Peregrina K; Brew I; Tosti E; Shaffer K; Tyler PC; Edelmann W; Augenlicht LH; Schramm VL
    J Biol Chem; 2024 Jan; 300(1):105492. PubMed ID: 38000655
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Stabilization and activation of p53 downregulates mTOR signaling through AMPK in mantle cell lymphoma.
    Drakos E; Atsaves V; Li J; Leventaki V; Andreeff M; Medeiros LJ; Rassidakis GZ
    Leukemia; 2009 Apr; 23(4):784-90. PubMed ID: 19225536
    [TBL] [Abstract][Full Text] [Related]  

  • 47.
    Eskelund CW; Dahl C; Hansen JW; Westman M; Kolstad A; Pedersen LB; Montano-Almendras CP; Husby S; Freiburghaus C; Ek S; Pedersen A; Niemann C; Räty R; Brown P; Geisler CH; Andersen MK; Guldberg P; Jerkeman M; Grønbæk K
    Blood; 2017 Oct; 130(17):1903-1910. PubMed ID: 28819011
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Cotargeting of BTK and MALT1 overcomes resistance to BTK inhibitors in mantle cell lymphoma.
    Jiang VC; Liu Y; Lian J; Huang S; Jordan A; Cai Q; Lin R; Yan F; McIntosh J; Li Y; Che Y; Chen Z; Vargas J; Badillo M; Bigcal JN; Lee HH; Wang W; Yao Y; Nie L; Flowers CR; Wang M
    J Clin Invest; 2023 Feb; 133(3):. PubMed ID: 36719376
    [TBL] [Abstract][Full Text] [Related]  

  • 49. PRMT5 Modulates Splicing for Genome Integrity and Preserves Proteostasis of Hematopoietic Stem Cells.
    Tan DQ; Li Y; Yang C; Li J; Tan SH; Chin DWL; Nakamura-Ishizu A; Yang H; Suda T
    Cell Rep; 2019 Feb; 26(9):2316-2328.e6. PubMed ID: 30811983
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Dual targeting of the cyclin/Rb/E2F and mitochondrial pathways in mantle cell lymphoma with the translation inhibitor silvestrol.
    Alinari L; Prince CJ; Edwards RB; Towns WH; Mani R; Lehman A; Zhang X; Jarjoura D; Pan L; Kinghorn AD; Grever MR; Baiocchi RA; Lucas DM
    Clin Cancer Res; 2012 Sep; 18(17):4600-11. PubMed ID: 22791882
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Activation of the p53-MDM4 regulatory axis defines the anti-tumour response to PRMT5 inhibition through its role in regulating cellular splicing.
    Gerhart SV; Kellner WA; Thompson C; Pappalardi MB; Zhang XP; Montes de Oca R; Penebre E; Duncan K; Boriack-Sjodin A; Le B; Majer C; McCabe MT; Carpenter C; Johnson N; Kruger RG; Barbash O
    Sci Rep; 2018 Jun; 8(1):9711. PubMed ID: 29946150
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Pevonedistat, a NEDD8-activating enzyme inhibitor, is active in mantle cell lymphoma and enhances rituximab activity in vivo.
    Czuczman NM; Barth MJ; Gu J; Neppalli V; Mavis C; Frys SE; Hu Q; Liu S; Klener P; Vockova P; Czuczman MS; Hernandez-Ilizaliturri FJ
    Blood; 2016 Mar; 127(9):1128-37. PubMed ID: 26675347
    [TBL] [Abstract][Full Text] [Related]  

  • 53. In vivo growth of mantle cell lymphoma xenografts in immunodeficient mice is positively regulated by VEGF and associated with significant up-regulation of CD31/PECAM1.
    Molinský J; Klánová M; Maswabi B; Soukup T; Trněný M; Nečas E; Živný J; Klener P
    Folia Biol (Praha); 2013; 59(1):26-31. PubMed ID: 23537525
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The miRNA-17∼92 cluster mediates chemoresistance and enhances tumor growth in mantle cell lymphoma via PI3K/AKT pathway activation.
    Rao E; Jiang C; Ji M; Huang X; Iqbal J; Lenz G; Wright G; Staudt LM; Zhao Y; McKeithan TW; Chan WC; Fu K
    Leukemia; 2012 May; 26(5):1064-72. PubMed ID: 22116552
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Activation of mammalian target of rapamycin signaling promotes cell cycle progression and protects cells from apoptosis in mantle cell lymphoma.
    Peponi E; Drakos E; Reyes G; Leventaki V; Rassidakis GZ; Medeiros LJ
    Am J Pathol; 2006 Dec; 169(6):2171-80. PubMed ID: 17148679
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Toll-like receptor-4 signaling in mantle cell lymphoma: effects on tumor growth and immune evasion.
    Wang L; Zhao Y; Qian J; Sun L; Lu Y; Li H; Li Y; Yang J; Cai Z; Yi Q
    Cancer; 2013 Feb; 119(4):782-91. PubMed ID: 22915070
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Protein arginine methyltransferase 5 has prognostic relevance and is a druggable target in multiple myeloma.
    Gullà A; Hideshima T; Bianchi G; Fulciniti M; Kemal Samur M; Qi J; Tai YT; Harada T; Morelli E; Amodio N; Carrasco R; Tagliaferri P; Munshi NC; Tassone P; Anderson KC
    Leukemia; 2018 Apr; 32(4):996-1002. PubMed ID: 29158558
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Novel selective inhibitors of nuclear export CRM1 antagonists for therapy in mantle cell lymphoma.
    Zhang K; Wang M; Tamayo AT; Shacham S; Kauffman M; Lee J; Zhang L; Ou Z; Li C; Sun L; Ford RJ; Pham LV
    Exp Hematol; 2013 Jan; 41(1):67-78.e4. PubMed ID: 22986101
    [TBL] [Abstract][Full Text] [Related]  

  • 59. PRMT5 Regulates DNA Repair by Controlling the Alternative Splicing of Histone-Modifying Enzymes.
    Hamard PJ; Santiago GE; Liu F; Karl DL; Martinez C; Man N; Mookhtiar AK; Duffort S; Greenblatt S; Verdun RE; Nimer SD
    Cell Rep; 2018 Sep; 24(10):2643-2657. PubMed ID: 30184499
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The Signal Transducer and Activator of Transcription 5B (STAT5B) Gene Promotes Proliferation and Drug Resistance of Human Mantle Cell Lymphoma Cells by Activating the Akt Signaling Pathway.
    Zhang W; Liang X; Gong Y; Xiao C; Guo B; Yang T
    Med Sci Monit; 2019 Apr; 25():2599-2608. PubMed ID: 30964854
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.